A Phase III Randomized Placebo-Controlled Study to Examine

Recruiting

99 years or below

All

Phase 3

1 Location

Brief description of study

This purpose of this study is to see if an investigational inhaled medication is safe and effective for the treatment of parainfluenza virus(PIV) in patients with weakened immune systems. Key eligibility criteria are being diagnosed with PIV having received a solid organ or stem cell transplant at any time in the past, or past history of being treated with chemotherapy for solid tumor or blood-related malignancy. The main study intervention is treatment with study drug or placebo for 7-10 days.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: PIV, cancer history
Age: 99 years or below
Gender: All

Updated on 11 Sep 2019. Study ID: 833645

Find a site

Your Information has been sent successfully.

Message sent successfully.

We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.

If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects

Brief description of study

Eligibility of study

Find a site